SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-049169
Filing Date
2022-02-23
Accepted
2022-02-23 06:35:33
Documents
14
Period of Report
2022-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d284356d8k.htm   iXBRL 8-K 25315
2 EX-99.1 d284356dex991.htm EX-99.1 67393
6 GRAPHIC g284356g19i51.jpg GRAPHIC 9326
  Complete submission text file 0001193125-22-049169.txt   238544

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20220223.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20220223_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20220223_pre.xml EX-101.PRE 11725
8 EXTRACTED XBRL INSTANCE DOCUMENT d284356d8k_htm.xml XML 3472
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 22660534
SIC: 2834 Pharmaceutical Preparations